Abstract:ID 131403 Poster Board 569 Chemokine receptors 2 and 5 (CCR2 and CCR5, respectively) are highly homologous G-protein coupled receptors on the surface of select immune cells with distinct functions and endogenous agonists but with select shared antagonists. These chemokine receptors are promising targets for small molecule therapeutics in the treatment of various cancers and autoimmune diseases, despite only one currently approved therapeutic for CCR5. Rational design of future therapeutics relies on a structural understanding of the determinants of antagonist selectivity as high affinity targeting of only one receptor is often desired. Further complicating therapeutic development, antagonists of human CCR2 (hCCR2) are often inactive to mouse CCR2 (mCCR2). Here, through rationally-guided gain-of-function mutagenesis, we characterized the molecular determinants of CCR2/CCR5 and human/mouse antagonist selectivity. Binding poses for a panel of selective and dual-specific antagonists were generated through molecular docking. Using these poses, we hypothesized that a single bulky residue in TM2 of hCCR5 (Y892.63) and mCCR2 (Y1142.63) dictates selectivity by obstructing binding of the minor pocket-targeting orthosteric antagonists with large substituents. By contrast, the corresponding S1012.63 of hCCR2 is permissive to the binding of such antagonists because it allows them to occupy space otherwise filled by tyrosine. To validate this hypothesis, we introduced a Y892.63S mutation into human CCR5 and tested the ability of a previously CCR2-selective antagonist cherney08a_22 to inhibit chemokine-induced suppression of forskolin-stimulated cAMP in HeLa cells expressing the mutant. Intracellular cAMP levels were measured with the BRET-based CAMYEL reporter. These experiments confirmed that indeed the CCR5(Y892.63S) mutant became sensitive to cherney08a_22 . We also demonstrated how the same residue could impart selectivity against human CCR5 and mouse CCR2 to antagonists with a medium-size (acetamide) substituent. An alternative hypothesis was assessed for CCR2-selective antagonists predicted to bind towards TM5 and the major pocket. Selectivity for these hCCR2 antagonists was suspected to be conveyed by residues F1093.33, S18045.52, or I1985.42 of human CCR5, which are distinct from their CCR2 counterparts. However, the introduction of CCR2-mimicking F1093.33H and S18045.52P mutations in hCCR5 was not sufficient to produce sensitivity to major pocket-targeting CCR2-selective antagonist PF-4136309 . We therefore concluded that its selectivity mechanism is due to the hCCR2 residue R2065.42 which is I1985.42 in hCCR5. Our findings provide a better framework for the rational development of selective and dual-affinity antagonists for CCR2 and CCR5 to overcome past deficiencies in design of potent and selective inhibitors.

Rational Design of De Novo CCL2 Binding Peptides

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

Novel Anti-Inflammatory Peptides Based on Chemokine-Glycosaminoglycan Interactions Reduce Leukocyte Migration and Disease Severity in a Model of Rheumatoid Arthritis

Rational Design of High Affinity Interaction Between CC Chemokine Binding Protein vCCI and CCL17/TARC

Molecular Insights into Ligand Recognition and Activation of Chemokine Receptors CCR2 and CCR3

Molecular Mechanisms of Antagonist Selectivity Against CCR2 and CCR5

Biophysical characterization of the CXC chemokine receptor 2 ligands

A unique ligand-steered strategy for CC chemokine receptor 2 homology modeling to facilitate structure-based virtual screening

A New Class Of Chemokine Analogs As Useful Research Tools To Study Chemokine Receptor Function And Promising Therapeutic Agents.

Modulating Macrophage Polarization through CCR2 Inhibition and Multivalent Engagement.

The molecular structure and role of CCL2 (MCP‐1) and C‐C chemokine receptor CCR2 in skeletal biology and diseases

Generation, characterization and biological activity of CCL2 (MCP-1/JE) and CCL12 (MCP-5) specific antibodies

Discovery of Cyclic Peptide Inhibitors Targeted on TNFα-TNFR1 from Computational Design and Bioactivity Verification

De novo design of miniprotein antagonists of cytokine storm inducers

Noncanonical roles of chemokine regions in CCR9 activation revealed by structural modeling and mutational mapping

More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis

A fluorescence polarization assay for the experimental validation of an in silico model of the chemokine CXCL8 binding to receptor-derived peptides

Design and optimisation of bioactive cyclic peptides: generation of a down-regulator of TNF secretion

A rational search for discovering potential neutraligands of human complement fragment 5a (hC5a)

Computational design of cyclic peptides to inhibit protein-peptide interactions

Exploring the CXCR3 Chemokine Receptor with Small-Molecule Antagonists and Agonists